SynthesisOncotarget2015
MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis.
Synthesis in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- MiRNAs with prognostic significance in multiple myeloma: A systemic review and meta-analysis.Medicine · 2019Pooled it
- Using microRNAs as Novel Predictors of Urologic Cancer Survival: An Integrated Analysis.EBioMedicine · 2018Pooled it
- MicroRNA expression profiling of Xp11 renal cell carcinoma.Human pathology · 2017Pooled it
- MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis.Scientific reports · 2017Pooled it
- MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis.Medicine · 2017Pooled it
- Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.Current urology reports · 2017Pooled it
- LncRNAs act as prognostic and diagnostic biomarkers in renal cell carcinoma: a systematic review and meta-analysis.Oncotarget · 2016Pooled it
- Prognostic role of microRNA-21 expression in gliomas: a meta-analysis.Journal of neuro-oncology · 2016Pooled it
- Review
- Regulatory mechanisms of mitochondrial function by cancer-derived exosomes in cachexia.Frontiers in oncology · 2026Article
- Machine learning-assisted radiogenomic analysis for miR-15a expression prediction in renal cell carcinoma.BMC cancer · 2025Article
- miR‑100: A key tumor suppressor regulatory factor in human malignant tumors (Review).International journal of molecular medicine · 2025Review
- The role of natural products versus miRNA in renal cell carcinoma: implications for disease mechanisms and diagnostic markers.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Expression of hsa-miRNA-15b, -99b, -181a and Their Relationship to Angiogenesis in Renal Cell Carcinoma.Biomedicines · 2024Article
- Potential upstream lncRNA-miRNA-mRNA regulatory network of the ferroptosis-related geneTranslational andrology and urology · 2023Article
- Methylation and expression levels of microRNA-23b/-24-1/-27b, microRNA-30c-1/-30e, microRNA-301a and let-7g are dysregulated in clear cell renal cell carcinoma.Molecular biology reports · 2021Article
- LINC00671 inhibits renal cell cancer progression via regulating miR-221-5p/SOCS1 axis.American journal of translational research · 2021Article
- Integrative p53, micro-RNA and Cathepsin Protease Co-Regulatory Expression Networks in Cancer.Cancers · 2020Review
- Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Article
- A rapid and reliable CE-LIF method for the quantitative analysis of miRNA-497 in plasma and organs and its application to a pharmacokinetic and biodistribution study.RSC advances · 2020Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is a systematic review of studies investigating the prognostic value of different microRNAs (miRs) in renal cell carcinoma (RCC). Twenty-seven relevant studies were identified, with a total of 2578 subjects. We found that elevated expression of miR-21, miR-1260b, miR-210, miR-100, miR-125b, miR-221, miR-630, and miR-497 was associated with a poor prognosis in RCC patients. Conversely, decreased expression of miR-106b, miR-99a, miR-1826, miR-215, miR-217, miR-187, miR-129-3p, miR-23b, miR-27b, and miR-126 was associated with a worse prognosis. We performed meta-analyses on studies to address the prognostic value of miR-21, miR-126, miR-210, and miR-221. This revealed that elevated miR-21 expression was associated with shorter overall survival (OS; hazard ratio [HR], 2.29; 95% confidence interval [CI], 1.28-4.08), cancer specific survival (CSS; HR, 4.16; 95% CI, 2.49-6.95), and disease free survival (DFS; HR, 2.15; 95% CI, 1.16-3.98). The decreased expression of miR-126 was associated with shorter CSS (HR, 0.35; 95% CI, 0.15-0.85), OS (HR, 0.45; 95% CI, 0.30-0.69), and DFS (HR 0.30; 95% CI, 0.18-0.50). Our comprehensive systematic review reveals that miRs, especially miR-21 and miR-126, could be promising prognostic markers and useful therapeutic targets in RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.